Medivir reports interim ASPIRE data

Medivir AB (SSE:MVIR B) reported interim 48-week data from the Phase IIb ASPIRE (C206) trial of TMC435 in 462 treatment-experienced patients with HCV genotype 1 infection. Once-daily TMC435 plus standard of care produced end of treatment response rates at week 48 of 92% in patients who had a prior relapse, 83% in prior partial responders and 71% in prior null responders vs. 70%, 17% and 25% for patients in each subgroup who received placebo plus standard of care. Additionally, 87%, 77% and 57% of patients in each subgroup achieved a sustained virologic response 4 weeks after the end of treatment vs. 50%, 11% and 23% of patients in each subgroup who received placebo plus standard of care. Standard of care is peginterferon alfa-2a and ribavirin. Medivir previously reported 4- and 24-week data from the trial (see BioCentury Extra, Nov. 18). ...